http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022109446-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a416da301af6529e8ad52a5249e6445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_88c409a0e2c97dcca4eaee76cbefe958 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5bcefa27f2bd9751b9e72d138e4749a1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-34 |
| filingDate | 2021-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bafbb17ddaa333e9d5abff44b3fd705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c07522354ea2e0977daa2ee92654847 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75e12b211ab016e02c9c7696116773a2 |
| publicationDate | 2022-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022109446-A1 |
| titleOfInvention | Extracellular vesicles derived from cardiosphere-derived cells as anti-shock therapeutics |
| abstract | The present invention generally relates to the use of extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs) as an anti-shock therapeutic. For instance, the present invention relates to a method of using CDC-EVs to treat polytrauma associated with coagulopathy and hemorrhagic shock in a subject in need thereof, wherein the lactate, glucose and/or creatinine levels in the subject are decreased upon being treated with a therapeutically effective amount of CDC-EVs. The results presented herein are of great relevance to the development of EV products for use in combat casualty care, as the studies presented herein show that CDC-EVs have the potential to be an anti-shock therapeutic if administered immediately after injury involving trauma associated with hemorrhagic shock and/or coagulopathy. |
| priorityDate | 2020-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 339.